ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

RVNC Revance Therapeutics Inc

3.0481
-0.1119 (-3.54%)
May 21 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,885,209
Bid Price 3.01
Ask Price 3.05
News -
Day High 3.1589

Low
2.90

52 Week Range

High
33.095

Day Low 2.98
Company Name Stock Ticker Symbol Market Type
Revance Therapeutics Inc RVNC NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.1119 -3.54% 3.0481 17:43:39
Open Price Low Price High Price Close Price Prev Close
3.13 2.98 3.1589 3.01 3.16
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
10,129 1,885,209 $ 3.05 $ 5,758,770 - 2.90 - 33.095
Last Trade Time Type Quantity Stock Price Currency
18:48:09 1 $ 3.04 USD

Revance Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
264.64M 88.21M - 234.04M -323.99M -3.67 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Revance Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No RVNC Message Board. Create One! See More Posts on RVNC Message Board See More Message Board Posts

Historical RVNC Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.403.652.903.262,721,269-0.3519-10.35%
1 Month3.654.4752.903.512,398,817-0.6019-16.49%
3 Months5.807.562.904.652,130,414-2.75-47.45%
6 Months7.379.7452.905.511,773,232-4.32-58.64%
1 Year31.8733.0952.9011.021,754,216-28.82-90.44%
3 Years28.4837.982.9017.741,268,443-25.43-89.30%
5 Years11.9037.982.9018.59981,591-8.85-74.39%

Revance Therapeutics Description

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are Product and the Service Segment. The Products segment generates maximum revenue which is engaged in the research and development of aesthetic and therapeutic products.

Your Recent History

Delayed Upgrade Clock